349 related articles for article (PubMed ID: 26438399)
1. Multiple sclerosis: relapses, resource use, and costs.
Hawton AJ; Green C
Eur J Health Econ; 2016 Sep; 17(7):875-84. PubMed ID: 26438399
[TBL] [Abstract][Full Text] [Related]
2. Burden of illness in multiple sclerosis (DEFENSE) study: the costs and quality-of-life of Finnish patients with multiple sclerosis.
Ruutiainen J; Viita AM; Hahl J; Sundell J; Nissinen H
J Med Econ; 2016; 19(1):21-33. PubMed ID: 26360615
[TBL] [Abstract][Full Text] [Related]
3. Costs and quality of life of multiple sclerosis in Switzerland.
Kobelt G; Berg J; Lindgren P; Gerfin A; Lutz J
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S86-95. PubMed ID: 17310338
[TBL] [Abstract][Full Text] [Related]
4. Costs and quality of life of multiple sclerosis in Austria.
Kobelt G; Berg J; Lindgren P; Plesnilla C; Baumhackl U; Berger T; Kolleger H; Vass K
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S14-23. PubMed ID: 17310339
[TBL] [Abstract][Full Text] [Related]
5. Costs and quality of life of multiple sclerosis in the United Kingdom.
Kobelt G; Berg J; Lindgren P; Kerrigan J; Russell N; Nixon R
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S96-104. PubMed ID: 17310341
[TBL] [Abstract][Full Text] [Related]
6. Costs and quality of life of multiple sclerosis in Italy.
Kobelt G; Berg J; Lindgren P; Battaglia M; Lucioni C; Uccelli A
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S45-54. PubMed ID: 17310336
[TBL] [Abstract][Full Text] [Related]
7. Costs and quality of life for patients with multiple sclerosis in Belgium.
Kobelt G
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S24-33. PubMed ID: 17318662
[TBL] [Abstract][Full Text] [Related]
8. Costs and quality of life of multiple sclerosis in Germany.
Kobelt G; Berg J; Lindgren P; Elias WG; Flachenecker P; Freidel M; König N; Limmroth V; Straube E
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S34-44. PubMed ID: 17310337
[TBL] [Abstract][Full Text] [Related]
9. Costs and quality of life in multiple sclerosis in The Netherlands.
Kobelt G; Berg J; Lindgren P; Anten B; Ekman M; Jongen PJ; Polman C; Uitdehaag B
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S55-64. PubMed ID: 17310343
[TBL] [Abstract][Full Text] [Related]
10. Costs and quality of life of multiple sclerosis in Sweden.
Berg J; Lindgren P; Fredrikson S; Kobelt G
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S75-85. PubMed ID: 17310342
[TBL] [Abstract][Full Text] [Related]
11. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from Turkey.
Karabudak R; Karampampa K; Calışkan Z;
J Med Econ; 2015 Jan; 18(1):69-75. PubMed ID: 25116693
[TBL] [Abstract][Full Text] [Related]
12. Costs and quality of life of multiple sclerosis in Spain.
Kobelt G; Berg J; Lindgren P; Izquierdo G; Sánchez-Soliño O; Pérez-Miranda J; Casado MA;
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S65-74. PubMed ID: 17310340
[TBL] [Abstract][Full Text] [Related]
13. Direct and indirect cost burden associated with multiple sclerosis relapses: excess costs of persons with MS and their spouse caregivers.
Parisé H; Laliberté F; Lefebvre P; Duh MS; Kim E; Agashivala N; Abouzaid S; Weinstock-Guttman B
J Neurol Sci; 2013 Jul; 330(1-2):71-7. PubMed ID: 23647840
[TBL] [Abstract][Full Text] [Related]
14. Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis.
Chiao E; Meyer K
Curr Med Res Opin; 2009 Jun; 25(6):1445-54. PubMed ID: 19422279
[TBL] [Abstract][Full Text] [Related]
15. Burden of a multiple sclerosis relapse: the patient's perspective.
Oleen-Burkey M; Castelli-Haley J; Lage MJ; Johnson KP
Patient; 2012; 5(1):57-69. PubMed ID: 22217263
[TBL] [Abstract][Full Text] [Related]
16. Healthcare Costs and Resource Utilization in Patients with Multiple Sclerosis Relapses Treated with H.P. Acthar Gel(®).
Gold LS; Suh K; Schepman PB; Damal K; Hansen RN
Adv Ther; 2016 Aug; 33(8):1279-92. PubMed ID: 27312977
[TBL] [Abstract][Full Text] [Related]
17. Societal costs of multiple sclerosis in Ireland.
Carney P; O'Boyle D; Larkin A; McGuigan C; O'Rourke K
J Med Econ; 2018 May; 21(5):425-437. PubMed ID: 29320900
[TBL] [Abstract][Full Text] [Related]
18. The cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis in Canada.
Su W; Kansal A; Vicente C; Deniz B; Sarda S
J Med Econ; 2016 Jul; 19(7):718-27. PubMed ID: 27080475
[TBL] [Abstract][Full Text] [Related]
19. Quantifying the relationship between increased disability and health care resource utilization, quality of life, work productivity, health care costs in patients with multiple sclerosis in the US.
Jones E; Pike J; Marshall T; Ye X
BMC Health Serv Res; 2016 Jul; 16():294. PubMed ID: 27443278
[TBL] [Abstract][Full Text] [Related]
20. Impact of multiple sclerosis phenotypes on burden of disease in Finland.
Purmonen T; Hakkarainen T; Tervomaa M; Ruutiainen J
J Med Econ; 2020 Feb; 23(2):156-165. PubMed ID: 31617776
[No Abstract] [Full Text] [Related]
[Next] [New Search]
